CARISMA Therapeutics (CARISMA Therapeutics) Net Margin % : -558.67% (As of Mar. 2024)

CARISMA Therapeutics Net Margin % Chart

CARISMA Therapeutics Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial							-759.85	-558.31	-559.26	-488.65	-558.67

Competitive Comparison of CARISMA Therapeutics's Net Margin %

For the Biotechnology subindustry, CARISMA Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's Net Margin % falls into.

CARISMA Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

CARISMA Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

CARISMA Therapeutics's Net Margin for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics  (NAS:CARM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

CARISMA Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics (CARISMA Therapeutics) Business Description